Mineralys Therapeutics, Inc. (MLYS)

Market Cap	614.15M
Revenue (ttm)	n/a
Net Income (ttm)	-153.25M
Shares Out	49.77M
EPS (ttm)	-3.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	432,107
Open	11.73
Previous Close	11.83
Day's Range	11.55 - 12.50
52-Week Range	7.37 - 16.91
Beta	n/a
Analysts	Strong Buy
Price Target	30.00 (+143.11%)
Earnings Date	Nov 11, 2024

About MLYS

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is he...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 10, 2023
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: MLYS
• Website: https://mineralystx.com

Analyst Forecast

According to 2 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price forecast is $30.0, which is an increase of 143.11% from the latest price.

Price Target

$30.0

(143.11% upside)

Analyst Consensus: Strong Buy